Karimi et al. showed similar levels of miR-326-3p in blood lymphocytes of MS patients with and without good clinical response to interferon-beta therapy, in contrast to previous reports showing miR-326-3p down-regulation in peripheral blood mononuclear cells of interferon-beta responders [18]. Here, IFNB1 is linked to myeloid sarcoma.